Document is current

Article History

Received: 18 April 2024

Accepted: 20 June 2024

First Online: 8 July 2024

Declarations

:

: Louis Bessette has been a speaker and consultant for Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Lilly, Novartis, Sanofi, Sandoz, Fresenius Kabi, Teva, Organon, and JAMP Pharma; and has received research grants from Amgen, BMS, Janssen, UCB, AbbVie, Pfizer, Celgene, Sanofi, Lilly, Novartis, Gilead, and JAMP Pharma. Brandusa Florica has been a speaker for AbbVie, BMS, Fresenius Kabi, Merck, Novartis, Pfizer, Roche, Sandoz, UCB; has been an advisory board advisor for AbbVie, Celltrion Healthcare, Jenssen, Pfizer; and has been a principal investigator for AbbVie, JAMP, Pharma, Jenssen, BMS, and Pfizer. Latha Naik declares no competing interests. Dalton Sholter has consulting relationships as a speaker and a consultant and for research with AbbVie, Amgen, BMS, Celgene, Gilead, JAMP, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, Sandoz, and UCB; and is a Partner with Rheumatology Research Associates, LTD (Phase 2, 3, 4 drug trials in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis). Pierre-André Fournier is an employee of AbbVie Corporation. Tanya Girard is an employee of AbbVie Corporation. Dalinda Liazoghli is an employee of AbbVie Corporation. Philip A. Baer has received consulting fees, speaker fees, or honoraria from AbbVie, Amgen, AstraZeneca, Eli Lilly, Fresenius Kabi, GSK, Innomar, JAMP Pharma, Janssen, McKesson, Novartis/Sandoz, and Pfizer.

: This study was conducted in accordance with the principles of Good Pharmacoepidemiology Practices and the ethical principles that have their origin in the Declaration of Helsinki. Institutional Review Board/Ethics Committee approval was obtained prior to study initiation as necessary per local regulations (Supplementary Table ). Informed consent was not required for this retrospective chart review of non-identifiable data.